The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular FDA mulls compounding for peptides previously flagged over safety risks BioSpace The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions BPC 157 Cost: What You Need to Know Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law